Burzynski and AACR (American Association for Cancer Research)

ANTINEOPLASTON
ANTINEOPLASTONS
AS2-1

2005 and 2004 References on AACR:

Molecular mechanisms of G1 cell arrest and induction of apoptosis augmented by treatment with ANTINEOPLASTON AS2-1 in colon cancer cells

[Proc Amer Assoc Cancer Res, Volume 46, 2005]

Experimental and Molecular Therapeutics 18:

Cell Cycle Mechanisms of Anticancer Drug Action

Abstract #2294

Keiko Matono, Yutaka Ogata and Kazuo Shirouzu

Kurume University School of madicine, Kurume City, Japan
http://www.aacrmeetingabstracts.org/cgi/content/abstract/2005/1/538-c

Antitumor effect of biochemical defense modifier ANTINEOPLASTON AS2-1 against colon cacer through G1 and G2 cell arrest

[Proc Amer Assoc Cancer Res, Volume 45, 2004]

Experimental and Molecular Therapeutics 27:

Natural Products

Abstract #2976

Keiko, M.
Matono Keiko

Kurume University, Kurume City, Japan
http://www.aacrmeetingabstracts.org/cgi/content/abstract/2004/1/688-a

PHENYLBUTYRATE
and
PHENYLACETATE

Cited by BURZYNSKI

2004 Reference on AACR:

PHENYLBUTYRATE and PHENYLACETATE Induce Differentiation and Inhibit Proliferation of Human Medulloblastoma Cells

Laboratory of Molecular Neuro-oncology

Cancer Genomics Program

Texas Children’s Cancer Center, Baylor College of Medicine, Houston, Texas

Clin Cancer Res 2004;10:1150-1159

doi: 10.1158/1078-0432.CCR-0747-3 Clin Cancer Res February 1, 2004 10; 1150

Clinical Cancer Research

(Cited by 55)
Abstract:
http://m.clincancerres.aacrjournals.org/content/10/3/1150.abstract
Article:
http://m.clincancerres.aacrjournals.org/content/10/3/1150.full
PDF:
http://m.clincancerres.aacrjournals.org/content/10/3/1150.full.pdf
Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/10/3/1150
Cited Articles by 48 articles, 20 of which you can access:
http://clincancerres.aacrjournals.org/content/10/3/1150.full.html#ref-list-1
cited by:
http://clincancerres.aacrjournals.org/content/10/3/1150.full.html#related-urls

PHENYLBUTYRATE

2001 (SAMID who learned from BURZYNSKI – 6 References) Reference on AACR:

A Phase I Dose Escalation and Bioavailability Study of Oral Sodium PHENYLBUTYRATE in Patients with Refractory Solid Tumor Malignancies

Divisions of Medical Oncology and Experimental Therapeutics, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland

NIH, Bethesda, Maryland

Clinical Cancer Research
http://m.clincancerres.aacrjournals.org/content/7/8/2292.full
2. ↵ … SAMID D.

Transcriptional upregulation of TGF-α by PHENYLACETATE and PHENYLBUTYRATE is associated with differentiation of human melanoma cells

Cytokine, 7: 449-456, 1995

Cytokine
Volume 7, Issue 5, July 1995, Pages 449–456
http://www.sciencedirect.com/science/article/pii/S1043466685700610
3. ↵ … SAMID D.

Transcriptional upregulation of γ globin by PHENYLBUTYRATE and analogous aromatic fatty acids

Biochem. Pharmacol., 52: 1227-1233, 1996

Biochemical Pharmacology
Volume 52, Issue 8, 25 October 1996, Pages 1227–1233
http://www.sciencedirect.com/science/article/pii/0006295296004765
5. ↵ SAMID D. …

Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of PHENYLACETATE

J. Clin. Investig., 91: 2288-2295, 1991

6. ↵ … SAMID D.

Activation of the human peroxisome proliferator-activated receptor by the antitumor agent PHENYLACETATE and its analogues

Biochem. Pharmacol., 52: 659-667, 1996

Biochemical Pharmacology
Volume 52, Issue 4, 23 August 1996, Pages 659–667
http://www.sciencedirect.com/science/article/pii/0006295296003401
15. ↵ … SAMID D. (Dvorit Samid)

The differentiating agent PHENYLACETATE increases prostate-specific antigen production by prostate cancer cells

Prostate, 29: 177-182, 1996

Article first published online: 7 DEC 1998

DOI: 10.1002/(SICI)1097-0045(199609)29:33.0.CO;2-B

The Prostate
Volume 29, Issue 3, pages 177–182, September 1996
http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0045(199609)29:3%3C177::AID-PROS3%3E3.0.CO;2-B/abstract;jsessionid=733C54B7B855391DFBB8C8E7F8EEA65D.d02t02
Cited by:
http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0045(199609)29:3%3C177::AID-PROS3%3E3.0.CO;2-B/citedby
20. ↵ SAMID D. …

The nuclear receptors PPARS as novel targets in differentiation therapy: activation by phenylacetate and phenylbutyrate

Anticancer Res., 17: 3927-3928, 1997

D SAMID (Who learned from BURZYNSKI)

PHENYLACETATE

Cited by BURZYNSKI

1996 Reference on AACR:

Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by PHENYLACETATE

Cell Growth and Differentiation, Vol 7, Issue 12 1609-1615, 1996
American Association of Cancer Research

… D SAMID …

Laboratory of Cellular and Molecular Biology, Gerontology Research Center, National Institute on Aging, NIH, Baltimore, Maryland, USA
http://cgd.aacrjournals.org/cgi/content/abstract/7/12/1609
S. R. BURZYNSKI …

Long-term Survival of High-Risk Pediatric Patients With Primitive Neuroectodermal Tumors Treated With ANTINEOPLASTONS A10 and AS2-1

Integr Cancer Ther, June 1, 2005; 4(2): 168 – 177

Integrative Cancer Therapies
http://ict.sagepub.com/content/4/2/168.abstract
S. R. BURZYNSKI

The Present State of ANTINEOPLASTON Research (1)

Integr Cancer Ther, March 1, 2004; 3(1): 47 – 58

doi: 10.1177/1534735403261964 Integr Cancer Ther March 2004 vol. 3 no. 1 47-58

Integrative Cancer Therapies
http://m.ict.sagepub.com/content/3/1/47.abstract

Sodium PHENYLACETATE

Cited by BURZYNSKI

1995 Reference on AACR:

Sodium PHENYLACETATE Induces Growth Inhibition and Bcl-2 Down-Regulation and Apoptosis in MCF7ras Cells in Vitro and in Nude Mice

Institut d’Oncologie Moléculaire et Cellulaire Humaine, 129 av. de Stalingrad, Bobigny

Université Paris Nord, 74 rue Marcel Cachin, Bobigny

Service d’Anatomie Pathologique

Clinique Universitaire de Cancérologie, 125 av. de Stalingrad, Bobigny, France

[Cancer Research 55, 5156-5160, November 15, 1995]

1995 American Association for Cancer Research
http://hwmaint.cancerres.aacrjournals.org/cgi/content/abstract/55/22/5156
S. R. BURZYNSKI …

Long-term Survival of High-Risk Pediatric Patients With Primitive Neuroectodermal Tumors Treated With ANTINEOPLASTONS A10 and AS2-1

Integr Cancer Ther, June 1, 2005; 4(2): 168 – 177

Integrative Cancer Therapies
http://ict.sagepub.com/content/4/2/168.abstract

S. R. BURZYNSKI

The Present State of ANTINEOPLASTON Research (1)

Integr Cancer Ther, March 1, 2004; 3(1): 47 – 58

doi: 10.1177/1534735403261964 Integr Cancer Ther March 2004 vol. 3 no. 1 47-58

Integrative Cancer Therapies
http://m.ict.sagepub.com/content/3/1/47.abstract

Cited by BURZYNSKI

2002 Reference on AACR:

Hypermethylation of HIC-1 and 17p Allelic Loss in Medulloblastoma

Departments of Pediatric Hematology/Oncology
and Pediatric Neurosurgery,
Children’s Research Institute, Children’s National Medical Center, Washington, D.C.

[Cancer Research 62, 3794-3797, July 1, 2002]

2002 American Association for Cancer Research

Molecular Biology and Genetics
http://hwmaint.cancerres.aacrjournals.org/cgi/content/full/62/13/3794
S. R. BURZYNSKI …

Long-term Survival of High-Risk Pediatric Patients With Primitive Neuroectodermal Tumors Treated With ANTINEOPLASTONS A10 and AS2-1

Integr Cancer Ther, June 1, 2005; 4(2): 168 – 177

Integrative Cancer Therapies
http://ict.sagepub.com/content/4/2/168.abstract

Burzynski, China, and Dvorit D. Samid

12/17/2012 – China
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524164
CDA-2 (cell differentiation agent 2), a URINARY preparation

CDA-2 and its main component PHENYLACETYLGLUTAMINE (PG or PAG)

Antineoplaston AS2-5 is PHENYLACETYLGLUTAMINE (PAG or PG)

Antineoplaston AS2-1 is a 4:1 mixture of phenylacetic acid (PA) and PHENYLACETYLGLUTAMINE (PAG or PG)

Antineoplastons AS2-5 and AS2-1 are derived from Antineoplaston A10

BURZYNSKI Reference: 22.
antineoplaston AS21

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052117
National Cancer Institute, at the National Institutes of Health cancer . gov web-site re Antineoplastons:
http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page5
PHENYLACETYLGLUTAMINE (PAG or PG)

Antineoplaston AS2-5 is PHENYLACETYLGLUTAMINE (PAG or PG)

Antineoplaston AS2-1 is a 4:1 mixture of phenylacetic acid (PA) and PHENYLACETYLGLUTAMINE (PAG or PG)

Antineoplastons AS2-5 and AS2-1 are derived from Antineoplaston A10

PHENYLACETYLGLUTAMINE (PAG or PG) and Phenylacetate (PN) are metabolites of Phenylbutyrate (PB) and are constituents of antineoplaston AS2-1

4/1994 – Dvorit D. SAMID et al.
A phase I … study of intravenous phenylacetate (PN) in patients with cancer

Cancer Res 54(7):1690-4 (1994), PMID 8137283

Cancer Res. 1994 Apr 1;54(7):1690-4

Clinical Pharmacology Branch, National Cancer Institute, NIH, Bethesda, Maryland
http://www.ncbi.nlm.nih.gov/m/pubmed/8137283
Phenylacetate (PN) elimination was accounted for by conversion to PHENYLACETYLGLUTAMINATE (PG or PAG), which was excreted in the urine

4/1995 – Dvorit D. SAMID et al.
Disposition of Phenylbutyrate (PB) and its metabolites Phenylacetate (PN) and PHENYLACETYLGLUTAMINATE (PG or PAG)

J Clin Pharmacol 35(4):368-73 (1995), PMID 7650225

J Clin Pharmacol. 1995 Apr;35(4):368-73

Pharmacy Department, National Institutes of Health, Bethesda, Maryland, USA
http://www.ncbi.nlm.nih.gov/m/pubmed/7650225
PHENYLACETYLGLUTAMINATE (PG or PAG) and Phenylacetate (PN) are metabolites of Phenylbutyrate (PB) and are constituents of AS2-1